Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Review Source Type: research

Related Links:

ConclusionPatiromer decreased serum K+ through 52 weeks in patients with hyperkalemia, chronic kidney disease, and heart failure with EF>40%, all of whom were taking RAAS inhibitors. These post-hoc results require prospective evaluation, but suggest that patiromer allows control of hyperkalemia in heart failure patients with EF>40% on RAAS inhibitors.ResultOverall, 55 out of 306 randomized patients had heart failure with EF>40% (100% Caucasian, 75% male, 69% ≥65 years of age). Mean (SD) EF was 48 (7)% and mean (SD) eGFR was 41 (13) mL/min/1.73 m² at baseline. All patients had hypertension (mean BP 155/83 m...
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
ConclusionsIn Asian patients from EMPA ‐REG OUTCOME®, empagliflozin improved kidney outcomes, slowed eGFR decline and lowered albuminuria versus placebo, consistent with the overall trial population findings.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Original Article Source Type: research
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterized as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death; it is associated with extrahepatic manifestations such as chronic kidney disease cardiovascular disease and sleep apnea.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Public Health Source Type: research
Diabetes is a major cause of end stage renal disease (ESRD), yet the natural history of diabetic kidney disease is not well understood. We aimed to identify patterns of estimated GFR (eGFR) trajectory and to determine the clinical and genetic factors and their associations of these different patterns with all-cause mortality in patients with type 2 diabetes. Among 6330 patients with baseline eGFR>60 ml/min per 1.73 m2 in the Hong Kong Diabetes Register, a total of 456 patients (7.2%) developed Stage 5 chronic kidney disease or ESRD over a median follow-up of 13 years (incidence rate 5.6 per 1000 person-years).
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Clinical Investigation Source Type: research
Publication date: Available online 6 November 2018Source: The Lancet Diabetes &EndocrinologyAuthor(s): Dick de Zeeuw, Ronny W Renfurm, George Bakris, Peter Rossing, Vlado Perkovic, Fan Fan Hou, Masaomi Nangaku, Kumar Sharma, Hiddo J L Heerspink, Alberto Garcia-Hernandez, Tobias E LarssonSummaryBackgroundMany patients with diabetic kidney disease have residual albuminuria and are at risk of disease progression. The ALBUM trial investigated the efficacy of a novel, orally active inhibitor of vascular adhesion protein-1, ASP8232, compared with placebo for reducing albuminuria in individuals with type 2 diabetes and chroni...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
AbstractThe American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascu...
Source: Diabetologia - Category: Endocrinology Source Type: research
ConclusionsThis study confirms the high prevalence of CKD in patients with multiple comorbidities: T2D and CVD. It also provides estimates of the prevalence of CKD categories based on KDIGO 2012 classification for US adults with T2D.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: Available online 3 November 2018Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Vadim V. Klimontov, Anton I. KorbutAbstractA growing body of evidence supports a shift in the natural history of chronic kidney disease (CKD) in subjects with diabetes. Specifically, normoalbuminuric chronic kidney disease (NA-CKD), which is characterized by a decline in the glomerular filtration rate in the absence of a preceding or accompanying elevation of albuminuria, has become a widely prevalent variant of renal impairment in diabetes. Diabetic women and nonsmoking individuals with bett...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Background: Type 2 Diabetes Mellitus (T2DM) is the main risk factor for Chronic Kidney Disease(CKD). With the increased prevalence of obesity in recent decades, the incidence of CKD has exponentially increased. Our goal in this study is to demonstrate how bariatric surgery affects glomerular filtration rate in T2DM patients and compare it with non-diabetic patients.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Source Type: research
In conclusion, management of blood pressure both at office and home was found to be important for the reno-protective effects of sodium-glucose cotransporter 2 inhibitors along with strict blood pressure management. PMID: 30373408 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Hypertension - Category: Cardiology Authors: Tags: Clin Exp Hypertens Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Urology & Nephrology